← Leaderboards
Siddhartha De
7 Hills Pharma, Llc
$1,468,770
Attributed
$4,876,735
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2022–24$2M$1.5M$1M$500K$0
'22
'23
'24
Funding mix
By agency
NIH$4,876,735 · 2
By mechanism
R44$4,876,735 · 2
Top collaborators
- Upendra Marathi5 shared
- Nisha Jain Garg3 shared
- William Schary2 shared
- Michael Schotsaert2 shared
Most similar at 7 Hills Pharma, Llc
Same institution · by research overlap
- Peter Vanderslice$1,627,443
- William Schary$1,136,559
- Yared Hailemichael$667,133
Others in their field
Other Rising Stars on “Future”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Mari Ostendorf · University Of Washington$51,931,230
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- Eric M Benway · Woods Hole Oceanographic Institution$32,293,242
- Walt Lee$25,884,232
- Cyrus Wadia · Activate Global, Inc.$24,000,000
Research focus
FutureImmunityCessation Of LifeFormulationImmuneImmune ResponseAdjuvantCell MotilityClinical TrialsEffectivenessCell AdhesionAdaptive ImmunityAnimal ModelAntibody ResponseAntigen PresentationAntigen-Presenting CellsAntigensBiological AvailabilityChagas DiseaseClinical ResearchDoseDrug KineticsAluminum SulfateImmunogenicity
Grant awards (5)
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$997,867
R44 · FY2024 · AI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953,477
R44 · FY2024 · AI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$997,867
R44 · FY2023 · AI
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$928,224
R44 · FY2023 · AI
Integrin activator-adjuvanted DNA vaccine against Trypanosoma cruzi infection$999,300
R44 · FY2022 · AI